Company intelligence / Profile preview

Peptor

Ownership: Private
Development stage: Phase 2

Overview

Peptor was an Israeli biopharmaceutical company focused on developing peptide-based therapeutics using its proprietary SCAPL technology. Its lead programs targeted autoimmune diseases such as diabetes and rheumatoid arthritis. The company’s most advanced assets were discontinued prior to its merger with DeveloGen in May 2004. No products reached commercialization.

Therapeutic areas: GastroenterologyCardiovascularImmunologyEndocrinology
Modalities: PeptidesSmall molecule
Industry: Biotech

Drug pipeline

1 asset

DiaPep277

Phase 2

Indications: Type 1 diabetes, Autoimmune diseases

Partnerships

Aventis co-development partnership for a diabetes drug targeting latent autoimmune diabetes in adults and type I diabetes

Beyond the preview

Go deeper on Peptor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptor.

Explore the full profile